Celgene History

1986
Celgene Hisotry

Welcome to Celgene.

Celgene Corporation is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases in patients with limited treatment options. There are hundreds of clinical trials at major medical centers evaluating compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma (MM), myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), pancreatic cancer, non-small lung cancer and melanoma. In addition, several compounds are being evaluated as therapies for serious inflammatory diseases such as psoriasis and psoriatic arthritis.

In this slideshow you’ll see the history of Celgene unfold. The timeline will take you from our founding through our exponential growth over the past three decades.

Welcome to Celgene
1986
David Stirling, Ph.D. and Sol Barer,Ph.D. plant the seed that will become Celgene

TBD
1986
Celgene becomes an independent biotechnology company.

TBD
1987
Celgene IPO : Initial public offering

Celgene IPO
1988
Discovers novel enzyme for the stereoselective synthesis of chiral compounds

TBD
1990
Patent received for enzymatic chiral resolution technology that forms the basis of Chiral Chemicals Business

TBD
1991
Demonstrates biotreatment system

Sample Descirption title1
1992
Licenses patent for uses of thalidomide from Rockefeller University

TBD
1993
Clinical Trials results are published that suggest thalidomide might be effective in inhibiting the progression of HIV-1 and cachexia.

TBD
1993
Tests new compounds believed to increase efficacy and reduce side effects of thalidomide.

TBD
1994
Dr. Sol Barer named President and Chief Operating Officer

TBD
1995
Thalidomide FDA approval for AIDS Patients

Receives FDA approval for expanded access to thalidomide for AIDS patients suffering from cachexia.Please See full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
  THALOMID® (thalidomide) PI Visit the THALOMID® website
Thalidomide FDA approval for AIDS Patients
1996
John Jackson named Chief ExecutiveOfficer

John Jackson named CEO
1996
NDA filing for THALOMID®

Submits NDA for THALOMID®Please See full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
  THALOMID® (thalidomide) PI Visit the THALOMID® website
Sample Descirption title2
1996
Design and demonstration of newimmunomodulatory compounds,known as IMiDs® compounds

TBD
1996
Patent filing for REVLIMID®

First patent application led for REVLIMID®Please See full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
 REVLIMID® (lenalidomide) PI Visit the REVLIMID® website
Patent filing for REVLIMID®
1997
Jerry Zeldis, M.D., Ph.D., joins asCelgene’s first Chief Medical Officer

Jerry Zeldis Joins Celgene
1997
First Multiple Myeloma patient receives THALOMID® under compassionate use IND

Please See full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
  THALOMID® (thalidomide) PI Visit the THALOMID® website
TBD
1998
Forms S.T.E.P.S.® delivery program

TBD
1998
FDA Approval to market THALOMID® for ENL

Celgene receives approval from theFDA to market THALOMID® for ENL Please See full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
  THALOMID® (thalidomide) PI Visit the THALOMID® website
Sample Descirption title2
1998
Dr. David Stirling becomes first ChiefScientic Officer

TBD
1999
Bob Hugin joins Celgene as Chief Financial Officer

TBD
1999
New England Journal of Medicinepublishes landmark Multiple Myeloma paperinvolving THALOMID®

Please See full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
  THALOMID® (thalidomide) PI Visit the THALOMID® website
Sample Descirption title4
2000
Secondary public offering

Secondary public offering
2000
Acquires Signal Pharmaceuticals

Sample Descirption title6
2001
FOCALIN® receives FDA approval

<%--Please See full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
 REVLIMID® (lenalidomide) PI Visit the REVLIMID® website
--%>
Sample Descirption title1
2001
REVLIMID® is tested in three Phase I/II

REVLIMID® is tested in three Phase I/II clinical trials with Refractory Multiple Myeloma patients.Please See full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
 REVLIMID® (lenalidomide) PI Visit the REVLIMID® website
Sample Descirption title2
2002
Celgene initiates Phase III trials of REVLIMID®

Phase III trials of REVLIMID® begin. Please See full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
 REVLIMID® (lenalidomide) PI Visit the REVLIMID® website
Sample Descirption title3
2003
Celgene acquires Anthrogenesis
Bob Hariri, M.D., Ph.D., Chief ExecutiveOfficer, Celgene Cellular Therapeutics,joins Celgene.

Sample Descirption title4
2004
Celgene Headquarters move to Summit,New Jersey

Sample Descirption title5
2004
The FDA grants fast-track designation to REVLIMID® in bothMM and MD

Please See full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
 REVLIMID® (lenalidomide) PI Visit the REVLIMID® website
Sample Descirption title6
2005
Celgene is included in the NASDAQ 100.

Sample Descirption title1
2005
REVLIMID® FDA approval for treatment of del 5q MDS patients

REVLIMID® receives FDA approval for treatment of del 5q MDS patientsPlease See full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
 REVLIMID® (lenalidomide) PI Visit the REVLIMID® website
Sample Descirption title2
2005
FOCALIN XR® is approved by FDA totreat ADHD

Sample Descirption title3
2005
Internal decision to bring the clinicalbenefits of innovative therapies topatients around the world.

Sample Descirption title4
2006
THALOMID® plus dexamethasone receives FDA approval

THALOMID® plus dexamethasone receives FDA approval as a 1st Line Multiple Myeloma therapy. Sol Barer becomes Chief Executive Officer.Completion of campus in Boudry, SwitzerlandPlease See full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
 THALOMID® (thalidomide) PI Visit the THALOMID® website
Sample Descirption title5
2006
THALOMID® becomes First oral therapy to be approved for newly diagnosed MM.

First oral therapy to be approved for newly diagnosed Multiple Myeloma.Please See full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
 THALOMID® (thalidomide) PI Visit the THALOMID® website
Sample Descirption title6
2006
REVLIMID® plus dexamethasone FDA approval as a 2nd Line MM therapy

REVLIMID® plus dexamethasone receives FDA approval as a 2nd Line Multiple Myeloma therapy.Please See full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
 REVLIMID® (lenalidomide) PI Visit the REVLIMID® website
Sample Descirption title1
2006
Celgene is included in the S&P 500.

Sample Descirption title2
2007
REVLIMID® plus dexamethasone EMA Approval for treatment of MM

REVLIMID® plus dexamethasone approved by EMA and SwissMedic for treatment of Multiple Myeloma.Please See full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
 REVLIMID® (lenalidomide) PI Visit the REVLIMID® website
Sample Descirption title3
2007
Celgene's revenue surpasses $1 Billion

Sample Descirption title4
2008
First Phase II data reported inPsoriasis for Apremilast OralPluripotent Immunomodulator.

Sample Descirption title5
2008
First patient receives CCT’s humanplacenta-derived stem cells forAcute Lymphoblastic Leukemia, alandmark treatment.

Sample Descirption title6
2008
Celgene acquires Pharmion and begins marketing VIDAZA®

Please See full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
 VIDAZA® (azacitidine for injection) PI Visit the VIDAZA® website
Sample Descirption title1
2008
Celgene begins marketing VIDAZA®

The first and only drug to significantly improve survival in patients with high-risk MDS and subset of AML. Please See full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
 VIDAZA® (azacitidine for injection) PI Visit the VIDAZA® website
Sample Descirption title2
2008
VIDAZA® receives EMA approval

VIDAZA® receives EMA approval Please See full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
 VIDAZA® (azacitidine for injection) PI Visit the VIDAZA® website
Sample Descirption title3
2010
Bob Hugin becomes Celgene's Chief Executive Officer

Sample Descirption title4
2010
Perry Karsen becomes ChiefOperations Officer.

Sample Descirption title5
2010
Jackie Fouse becomes ChiefFinancial Officer.

Sample Descirption title6
2010
Establishes Celgene Institute of Translational Research Europe.

Sample Descirption title1
2010
Celgene Acquires GloucesterPharmaceuticals

Acquires Gloucester Pharmaceuticals and begins marketing ISTODAX® to treat cutaneous T-cell lymphoma Please See full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
 ISTODAX® (romidepsin) for injection PI Visit the ISTODAX® website
Sample Descirption title2
2010
Japan grants approval to market REVLIMID® for MM and del 5q MDS

Please See full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
 REVLIMID® (lenalidomide) PI Visit the REVLIMID® website
Sample Descirption title3
2010
Celgene acquires Abraxis BioScience

Sample Descirption title4
2010
Abraxane® becomes the first product utilizing nab® platformtechnology to be approved by the FDA and EMA.

Please See full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
 ABRAXANE® (for injectable suspension) PI Visit the ABRAXANE® website
Sample Descirption title4
2010
Celgene Completes $1.25 BillionDebt Offering

Sample Descirption title5
2011
Istodax receives FDA approval for the treatment of peripheral T-cell lymphoma.

Please See full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
 ISTODAX® (romidepsin) for injection PI Visit the ISTODAX® website
Sample Descirption title6
2012
Celgene acquires Avila Therapeutics.

Sample Descirption title1
2012 May
New England Journal of Medicine Reports on Three REVLIMID Phase III Trials in Patients with Newly Diagnosed Multiple Myeloma

Sample Descirption title2
2012 July
Apremilast Achieves Statistical Significance for the Primary Endpoint of the First Phase III Study – PALACE 1 – in Patients with Psoriatic Arthritis

Sample Descirption title3
2012 October
FDA Approves ABRAXANE for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer

Please See full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
 ABRAXANE® Abraxane PI Visit the Abraxane® website
Sample Descirption title4
2012 October
Abraxane demonsrates significant Improvement in Progression Free Survival Compared to Standard Chemotherapy in Advanced Melanoma Patients

Please See full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
 ABRAXANE® Abraxane PI Visit the Abraxane® website
Sample Descirption title5
2013
Abraxane Plus Gemcitabine Demonstrates Significant Survival Advantage in Phase 3 Study of Patients with Advanced Pancreatic Cancer

Please See full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
 ABRAXANE® Abraxane PI Visit the Abraxane® website
Sample Descirption title7
2013 February
POMLYST approved by the U.S. FDA for the treatment of patients with multiple myeloma who have received at lease two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.

Please See full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.
 POMALYST® Pomalyst PI Visit the Pomalyst® website
Sample Descirption title7
-->